Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Andrew Evens, DO, MBA, MSc, discusses a modern way of stratifying risk in patients with early-stage Hodgkin lymphoma.

AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancersFORT MYERS, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- ...

Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...

Canine and human cancers bear many similarities, and studies on dogs are helping advance care for our furry friends and for ...

Caribou Biosciences' allogeneic CAR T-cell therapies show promising early efficacy and safety, but require clinical ...

Transmembrane proteins (TPs), also referred to as ‘integral membrane proteins’, make up between 70 % and 80 % of the total ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 billion by 2034.

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy ...

What's driving the shift to spatially resolved molecular analysis? The global in situ hybridization market, valued at USD 1.64 billion in ...

The biobank completed HLA typing; a close HLA match between donor and patient greatly reduces the risk of the body rejecting ...